Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio is a promising biotechnology company with a strong pipeline of innovative allogeneic gamma delta T cell therapies. With multiple upcoming catalysts, including a clinical data update for their CD20-targeted CAR-T therapy in 1H26 and FDA alignment on a pivotal trial design in 2Q26, the company is positioned for potential value inflection points. In addition, Adicet's financial results were better than expected and they have a strong cash position to support operations into 2H27. Their lead product candidate, prulacabtagene leucel, has shown promising efficacy and a benign safety profile in lupus patients, setting it apart from competitors and potentially positioning it for success in a competitive autoimmune landscape. With risk-adjusted revenues for prula-cel already factored in, any additional indications could drive further upside for the company.

Bears say

Adicet Bio is facing an uncertain outlook due to their clinical product pipeline being in mid to late stage development, with no products currently on the market, and only two of their product candidates being studied in Phase 1 trials. Additionally, while they have a strong cash position currently, their high spending on research and development and general administrative expenses may jeopardize their financials in the long run. Due to these factors, the stock's reaction has been lackluster.

ACET has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 4 analysts, ACET has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.